- Home
- MCS vs BCYC Comparison
MCS vs BCYC Comparison
Compare MCS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- BCYC
- Stock Information
- Founded
- MCS 1935
- BCYC 2009
- Country
- MCS United States
- BCYC United Kingdom
- Employees
- MCS N/A
- BCYC N/A
- Industry
- MCS Movies/Entertainment
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- MCS Consumer Discretionary
- BCYC Health Care
- Exchange
- MCS Nasdaq
- BCYC Nasdaq
- Market Cap
- MCS 549.0M
- BCYC 511.4M
- IPO Year
- MCS N/A
- BCYC 2019
- Fundamental
- Price
- MCS $16.20
- BCYC $7.39
- Analyst Decision
- MCS Strong Buy
- BCYC Buy
- Analyst Count
- MCS 3
- BCYC 8
- Target Price
- MCS $23.33
- BCYC $29.14
- AVG Volume (30 Days)
- MCS 186.2K
- BCYC 438.9K
- Earning Date
- MCS 05-01-2025
- BCYC 05-01-2025
- Dividend Yield
- MCS 1.74%
- BCYC N/A
- EPS Growth
- MCS N/A
- BCYC N/A
- EPS
- MCS N/A
- BCYC N/A
- Revenue
- MCS $695,086,000.00
- BCYC $35,275,000.00
- Revenue This Year
- MCS $11.34
- BCYC N/A
- Revenue Next Year
- MCS $5.28
- BCYC $0.27
- P/E Ratio
- MCS N/A
- BCYC N/A
- Revenue Growth
- MCS 0.42
- BCYC 30.76
- 52 Week Low
- MCS $9.56
- BCYC $6.10
- 52 Week High
- MCS $23.16
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- MCS 44.61
- BCYC 40.27
- Support Level
- MCS $15.80
- BCYC $6.10
- Resistance Level
- MCS $16.42
- BCYC $8.00
- Average True Range (ATR)
- MCS 0.63
- BCYC 0.61
- MACD
- MCS 0.11
- BCYC 0.14
- Stochastic Oscillator
- MCS 60.81
- BCYC 46.07
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are Theatres and Hotels and Resorts. The Theatre segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio ands others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.